Ads
related to: neuroendocrine tumor injections nhs society of canada
Search results
Results From The WOW.Com Content Network
Lanreotide, sold under the brand name Somatuline among others, is a medication used in the management of acromegaly and symptoms caused by neuroendocrine tumors, most notably carcinoid syndrome. It is a long-acting analogue of somatostatin , like octreotide .
Within the broad category of neuroendocrine tumors there are many different tumor types, [10] representing only a small proportion of the tumors or cancers in most of these tissues [citation needed]: Pituitary gland: Neuroendocrine tumor of the anterior pituitary; Thyroid gland: Neuroendocrine thyroid tumors, particularly medullary carcinoma
Due to presence of these tumors, DIPNECH is classified as a pre-malignant condition. [1] Although there have been reports of atypical carcinoids with local lymph node involvement, there are no reports of more aggressive neuroendocrine tumors, such as large cell neuroendocrine or small cell lung cancer, associated with DIPNECH. [3]
Endocrine-Related Cancer was founded as Reviews on Endocrine-Related Cancer, the in-house journal of Zeneca (now AstraZeneca) published by its parent company ICI Pharmaceuticals. It was taken over by the Society for Endocrinology in 1994 when it was renamed, and the remit was extended to include a limited number of original research articles to ...
Neuroendocrine carcinoma of the cervix is best defined separately:Neuroendocrine: Of, relating to, or involving the interaction between the nervous system and the hormones of the endocrine glands. Carcinoma: An invasive malignant tumor derived from epithelial tissue that tends to metastasize to other areas of the body.
Large-cell neuroendocrine carcinoma of the lung (LCNEC of the lung), or pulmonary large-cell neuroendocrine carcinoma (PLCNC), is a highly malignant neoplasm arising from transformed epithelial cells originating in tissues within the pulmonary tree. It is currently considered to be a subtype of large-cell lung carcinoma.
The new 2019 WHO classification and grading criteria for neuroendocrine tumors of the digestive system grades all the neuroendocrine tumors into three grades, based on their degree of cellular differentiation (from well-differentiated NET grade (G)1 to G3, and poorly-differentiated neuroendokrina cancer, NEC G3), morphology, mitotic rate and Ki ...
Multiple endocrine neoplasia (abbreviated MEN) is a condition which encompasses several distinct syndromes featuring tumors of endocrine glands, each with its own characteristic pattern. In some cases, the tumors are malignant, in others, benign. Benign or malignant tumors of nonendocrine tissues occur as components of some of these tumor ...